BEAM: Gene editing pipeline advances with BEAM-302, BEAM-304, and risto-cel nearing pivotal milestones
The company is advancing a robust gene editing portfolio with lead programs in AATD, PKU, and sickle cell, leveraging next-gen base editing and integrated manufacturing. BEAM-302 and BEAM-304 show strong clinical and preclinical promise, with pivotal trials and commercial launches on track.Based on…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.